Momentum Biotechnologies, a CRO for mass spectrometry-based drug discovery, and Cube Biotech, a company specializing in membrane protein targets, have entered a strategic partnership to support clients’ novel therapeutic solutions. The collaboration combines Cube’s protein technology platforms, which enable difficult membrane proteins to be synthesized and purified without compromising native structure, with Momentum’s ability to identify and develop promising clinical leads through ...